About Eris Lifesciences Limited
Data last updated: 18 December 2025
Eris Lifesciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 25 January 2007, the company has been in operation for over 19 years.
Registered with ROC Ahmedabad under CIN L24232GJ2007PLC049867. Listed on BSE: 540596 and NSE: ERIS.
Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹13.62 Cr. Formerly known as Eris Lifesciences Private Limited and Eris Lifescience Private Limited. It is led by directors including Kalpana Vasantrai Unadkat and Sachin Shah.
Last AGM: 25 September 2024. Financial statements filed for year ended 31 March 2025. Office: Shivarth Ambit Plot No 142/2 Ramdas Road Off Sbr Near Swati Bungalows Bodakdev, Ahmedabad, Gujarat, India – 380054.
As per the financials filed for FY 2025, the company reported a revenue of ₹2,912 Cr, a growth of 43% compared to the previous year.
The company has a workforce of approximately 3,131 employees as per the latest available data. Its group structure includes 6 subsidiaries.
The company is associated with 1 brand - Eris Life Sciences. As per MCA filings, the company has open charges of ₹1,524.82 Cr and satisfied charges of ₹1,252.5 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website eris.co.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressShivarth Ambit Plot No 142/2 Ramdas Road Off Sbr Near Swati Bungalows Bodakdev, Ahmedabad, Gujarat, India – 380054
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Eris Lifesciences Limited
Eris Lifesciences Limited has undergone 2 name changes throughout its history. The company was previously known as Eris Lifesciences Private Limited, and Eris Lifescience Private Limited. The current legal name is Eris Lifesciences Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Eris Lifesciences Limited | Current |
| Eris Lifesciences Private Limited | Previous |
| Eris Lifescience Private Limited | Previous |
CIN History of Eris Lifesciences Limited
Eris Lifesciences Limited has one previous CIN (Corporate Identification Number): U24232GJ2007PLC049867. The current CIN is L24232GJ2007PLC049867, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232GJ2007PLC049867 | Current |
| U24232GJ2007PLC049867 | Previous |
Associated Brands with Eris Lifesciences Limited
Eris Lifesciences Limited operates one associated brand: ERIs Life Sciences. These brands represent Eris Lifesciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations for chronic diseases are manufactured and studied. | eris.co.in |
Business Activity of Eris Lifesciences Limited
Eris Lifesciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Eris Lifesciences Limited
Eris Lifesciences Limited is audited by Walker Chandiok &Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Walker Chandiok &Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Eris Lifesciences Limited
Eris Lifesciences Limited is currently managed by 10 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kalpana Vasantrai Unadkat | Director | 05 Jan 2021 | 5 Years 6 Months | Current |
|
Sachin Shah
Also directs:
Eris Healthcare Private Limited, Eris Therapeutics Limited, Aprica Healthcare Limited and 5 more
|
Cfo | 28 Sep 2016 | 9 Years 9 Months | Current |
| Vasudevan Sujesh | Director | 25 Jul 2022 | 3 Years 11 Months | Current |
| Amit Indubhushan Bakshi | Managing Director | 27 Jan 2007 | 19 Years 5 Months | Current |
|
Inderjeet Singh Negi
Also directs:
Eris Healthcare Private Limited, Eris Therapeutics Limited, Eris Bionxt Private Limited and 3 more
|
Whole-Time Director | 25 Jan 2007 | 19 Years 5 Months | Current |
| Prashant Gupta | Director | 30 Apr 2018 | 8 Years 2 Months | Current |
Financials of Eris Lifesciences Limited FY 2026 filings available
Eris Lifesciences Limited reported revenue of ₹3,129.42 Cr (up 8.15% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹3,129.42 Cr | ₹2,893.64 Cr | ₹2,009.14 Cr | ₹1,685.15 Cr | ₹1,347.04 Cr | ₹1,211.86 Cr | ₹1,074.06 Cr |
| Other Income | ₹7.75 Cr | ₹18.36 Cr | ₹23.82 Cr | ₹11.15 Cr | ₹26.09 Cr | ₹8.71 Cr | ₹15.4 Cr |
| Total Income | ₹3,137.17 Cr | ₹2,912 Cr | ₹2,032.96 Cr | ₹1,696.3 Cr | ₹1,373.14 Cr | ₹1,220.57 Cr | ₹1,089.46 Cr |
| Cost of Materials Consumed | ₹326.65 Cr | ₹276.34 Cr | ₹177.81 Cr | ₹142.2 Cr | ₹117.57 Cr | ₹99.43 Cr | ₹76.88 Cr |
| Purchases of Stock-in-Trade | ₹490.56 Cr | ₹473.12 Cr | ₹201.52 Cr | ₹206.33 Cr | ₹141.72 Cr | ₹177.01 Cr | ₹73.24 Cr |
| Changes in Inventories | -₹21.61 Cr | -₹35.47 Cr | ₹72.1 Lakh | ₹3.82 Cr | -₹77.6 Lakh | -₹38.17 Cr | ₹21.41 Cr |
| Employee Benefit Expense | ₹556.81 Cr | ₹505.09 Cr | ₹403.82 Cr | ₹346.16 Cr | ₹252.25 Cr | ₹229.3 Cr | ₹205.69 Cr |
| Finance Costs | ₹192.67 Cr | ₹231.29 Cr | ₹84.8 Cr | ₹26.17 Cr | ₹4.15 Cr | ₹1.8 Cr | ₹2.16 Cr |
| Depreciation & Amortisation | ₹279.5 Cr | ₹315.46 Cr | ₹182.61 Cr | ₹117.09 Cr | ₹64.71 Cr | ₹42.99 Cr | ₹50.26 Cr |
| Other Expenses | ₹656.9 Cr | ₹657.36 Cr | ₹550.45 Cr | ₹449.9 Cr | ₹351.32 Cr | ₹313.72 Cr | ₹328.46 Cr |
| Total Expenses | ₹2,481.48 Cr | ₹2,423.19 Cr | ₹1,601.72 Cr | ₹1,291.66 Cr | ₹930.94 Cr | ₹826.07 Cr | ₹758.11 Cr |
| Profit Before Exceptional Items & Tax | ₹655.69 Cr | ₹488.81 Cr | ₹431.24 Cr | ₹404.64 Cr | ₹442.2 Cr | ₹394.5 Cr | ₹331.35 Cr |
| Exceptional Items | -₹17.24 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹638.45 Cr | ₹488.81 Cr | ₹431.24 Cr | ₹404.64 Cr | ₹442.2 Cr | ₹394.5 Cr | ₹331.35 Cr |
| Total Tax Expense | -₹8.97 Cr | ₹114.2 Cr | ₹34.19 Cr | ₹30.48 Cr | ₹36.41 Cr | ₹39.36 Cr | ₹34.84 Cr |
| Net Profit | ₹647.51 Cr | ₹374.67 Cr | ₹397.05 Cr | ₹374.16 Cr | ₹405.79 Cr | ₹355.14 Cr | ₹296.51 Cr |
| attributable to Owners | ₹619.52 Cr | ₹351.84 Cr | ₹391.98 Cr | ₹382.16 Cr | ₹406.11 Cr | ₹355.14 Cr | - |
| attributable to NCI | ₹27.99 Cr | ₹22.83 Cr | ₹5.07 Cr | -₹8 Cr | -₹32.4 Lakh | ₹0 | - |
| Other Comprehensive Income | -₹1.44 Cr | -₹3.29 Cr | -₹3.05 Cr | ₹5.9 Lakh | -₹98.2 Lakh | -₹1.49 Cr | -₹1.22 Cr |
| Total Comprehensive Income | ₹646.07 Cr | ₹371.38 Cr | ₹394 Cr | ₹374.22 Cr | ₹404.81 Cr | ₹353.65 Cr | ₹295.29 Cr |
| EBITDA (computed) | ₹1,127.86 Cr | ₹1,035.56 Cr | ₹698.65 Cr | ₹547.9 Cr | ₹511.05 Cr | ₹439.28 Cr | ₹383.77 Cr |
| Basic EPS | ₹45.33 | ₹25.85 | ₹28.82 | ₹28.10 | ₹29.89 | ₹26.16 | ₹21.61 |
| Diluted EPS | ₹45.26 | ₹25.81 | ₹28.79 | ₹28.07 | ₹29.88 | ₹26.14 | ₹21.59 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹7,365.51 Cr | ₹7,033.17 Cr | ₹7,048.84 Cr | ₹3,667.33 Cr |
| Non-current Assets | ₹5,825.66 Cr | ₹5,770.64 Cr | ₹4,746.76 Cr | ₹2,902.61 Cr |
| Current Assets | ₹1,539.85 Cr | ₹1,262.53 Cr | ₹2,302.07 Cr | ₹764.72 Cr |
| Property, Plant & Equipment | ₹708.37 Cr | ₹662.07 Cr | ₹504.6 Cr | ₹356 Cr |
| Inventories | ₹436.82 Cr | ₹334.83 Cr | ₹189.03 Cr | ₹131.44 Cr |
| Trade Receivables | ₹680.34 Cr | ₹458.64 Cr | ₹422.02 Cr | ₹292.71 Cr |
| Cash & Equivalents | ₹54.74 Cr | ₹199.74 Cr | ₹94.25 Cr | ₹56.02 Cr |
| Equity (Net Worth) | ₹3,895.66 Cr | ₹3,271.76 Cr | ₹3,222.03 Cr | ₹2,220.68 Cr |
| Equity Share Capital | ₹13.85 Cr | ₹13.62 Cr | ₹13.6 Cr | ₹13.6 Cr |
| Borrowings (Non-current) | ₹955.83 Cr | ₹1,781.72 Cr | ₹654.51 Cr | ₹644.45 Cr |
| Borrowings (Current) | ₹1,353.85 Cr | ₹696.2 Cr | ₹2,080.76 Cr | ₹185.57 Cr |
| Total Debt (computed) | ₹2,309.68 Cr | ₹2,477.92 Cr | ₹2,735.27 Cr | ₹830.02 Cr |
| Current Liabilities | ₹2,077.1 Cr | ₹1,381.39 Cr | ₹2,532.08 Cr | ₹443.23 Cr |
| Total Liabilities | ₹3,469.85 Cr | ₹3,761.41 Cr | ₹3,826.81 Cr | ₹1,446.65 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹537.99 Cr | ₹1,065.01 Cr | ₹486.01 Cr | ₹291.74 Cr | ₹378.26 Cr |
| Investing Cash Flow | -₹369.46 Cr | -₹79.97 Cr | -₹1,827.56 Cr | -₹974.61 Cr | -₹319.61 Cr |
| Financing Cash Flow | -₹313.53 Cr | -₹881.32 Cr | ₹1,379.78 Cr | ₹688.03 Cr | -₹44.7 Cr |
| Capital Expenditure | ₹296.86 Cr | ₹155 Cr | ₹129.16 Cr | ₹841.42 Cr | ₹121.03 Cr |
| Free Cash Flow (computed) | ₹241.13 Cr | ₹910.01 Cr | ₹356.84 Cr | -₹549.68 Cr | ₹257.23 Cr |
| Dividends Paid | ₹0 | ₹100.05 Cr | ₹0 | ₹99.91 Cr | ₹81.62 Cr |
| Net Change in Cash | -₹145 Cr | ₹103.72 Cr | ₹38.22 Cr | ₹5.15 Cr | ₹13.96 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹756.56 Cr | ₹807.45 Cr | ₹792.41 Cr | ₹773 Cr | ₹705.3 Cr | ₹727.45 Cr | ₹738.95 Cr | ₹719.72 Cr | ₹550.93 Cr | ₹486.3 Cr | ₹505.3 Cr | ₹466.62 Cr |
| Other Income | ₹2.23 Cr | ₹2 Lakh | ₹2.81 Cr | ₹2.69 Cr | ₹7.95 Cr | ₹4.22 Cr | ₹6.77 Cr | ₹1.64 Cr | ₹15.15 Cr | ₹4.2 Cr | ₹3.48 Cr | ₹98.9 Lakh |
| Total Income | ₹758.79 Cr | ₹807.47 Cr | ₹795.22 Cr | ₹775.69 Cr | ₹713.25 Cr | ₹731.67 Cr | ₹745.72 Cr | ₹721.36 Cr | ₹566.07 Cr | ₹490.49 Cr | ₹508.78 Cr | ₹467.61 Cr |
| Cost of Materials Consumed | ₹68.12 Cr | ₹105.85 Cr | ₹82.58 Cr | ₹70.1 Cr | ₹68.28 Cr | ₹69.43 Cr | ₹72.16 Cr | ₹66.47 Cr | ₹51.17 Cr | ₹38.91 Cr | ₹48.17 Cr | ₹39.56 Cr |
| Purchases of Stock-in-Trade | ₹122.97 Cr | ₹117.24 Cr | ₹146.09 Cr | ₹104.26 Cr | ₹95.98 Cr | ₹133.22 Cr | ₹118.35 Cr | ₹125.57 Cr | ₹58.51 Cr | ₹50.03 Cr | ₹53.77 Cr | ₹39.2 Cr |
| Changes in Inventories | -₹5.84 Cr | ₹21 Lakh | -₹26.26 Cr | ₹10.28 Cr | ₹5.99 Cr | -₹25.77 Cr | -₹4.24 Cr | -₹11.45 Cr | ₹8.5 Cr | -₹6.9 Lakh | -₹7.34 Cr | -₹36.6 Lakh |
| Employee Benefit Expense | ₹136.85 Cr | ₹138.08 Cr | ₹137.45 Cr | ₹144.43 Cr | ₹121.45 Cr | ₹125.39 Cr | ₹125.63 Cr | ₹132.62 Cr | ₹102.48 Cr | ₹98.68 Cr | ₹98.53 Cr | ₹104.13 Cr |
| Finance Costs | ₹45.62 Cr | ₹48.82 Cr | ₹49.55 Cr | ₹48.68 Cr | ₹54.28 Cr | ₹57.17 Cr | ₹59.47 Cr | ₹60.37 Cr | ₹33.03 Cr | ₹18.12 Cr | ₹16.3 Cr | ₹17.36 Cr |
| Depreciation & Amortisation | ₹69.57 Cr | ₹70.34 Cr | ₹69.08 Cr | ₹70.51 Cr | ₹77.25 Cr | ₹81.2 Cr | ₹80.48 Cr | ₹75.94 Cr | ₹53.9 Cr | ₹45.72 Cr | ₹42.09 Cr | ₹40.89 Cr |
| Other Expenses | ₹160.89 Cr | ₹164.46 Cr | ₹164.34 Cr | ₹167.22 Cr | ₹161.21 Cr | ₹174.87 Cr | ₹164.76 Cr | ₹156.52 Cr | ₹181.84 Cr | ₹123.24 Cr | ₹131.03 Cr | ₹114.35 Cr |
| Total Expenses | ₹598.18 Cr | ₹645 Cr | ₹622.83 Cr | ₹615.48 Cr | ₹584.44 Cr | ₹615.51 Cr | ₹616.61 Cr | ₹606.04 Cr | ₹489.43 Cr | ₹374.62 Cr | ₹382.54 Cr | ₹355.13 Cr |
| Profit Before Exceptional Items & Tax | ₹160.61 Cr | ₹162.47 Cr | ₹172.39 Cr | ₹160.21 Cr | ₹128.81 Cr | ₹116.16 Cr | ₹129.11 Cr | ₹115.32 Cr | ₹76.65 Cr | ₹115.87 Cr | ₹126.24 Cr | ₹112.48 Cr |
| Exceptional Items | ₹0 | -₹17.24 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹160.61 Cr | ₹145.23 Cr | ₹172.39 Cr | ₹160.21 Cr | ₹128.81 Cr | ₹116.16 Cr | ₹129.11 Cr | ₹115.32 Cr | ₹76.65 Cr | ₹115.87 Cr | ₹126.24 Cr | ₹112.48 Cr |
| Total Tax Expense | -₹119.69 Cr | ₹36.52 Cr | ₹38.2 Cr | ₹36 Cr | ₹26.52 Cr | ₹29.23 Cr | ₹32.76 Cr | ₹25.9 Cr | -₹2.99 Cr | ₹14.41 Cr | ₹3.92 Cr | ₹18.84 Cr |
| Net Profit | ₹279.1 Cr | ₹108.83 Cr | ₹134.47 Cr | ₹125.1 Cr | ₹102.35 Cr | ₹86.93 Cr | ₹96.35 Cr | ₹89.42 Cr | ₹79.63 Cr | ₹101.46 Cr | ₹122.31 Cr | ₹93.65 Cr |
| attributable to Owners | ₹281.61 Cr | ₹99.72 Cr | ₹120.19 Cr | ₹117.99 Cr | ₹93.84 Cr | ₹83.63 Cr | ₹91.59 Cr | ₹83.18 Cr | ₹70.96 Cr | ₹102.74 Cr | ₹123.43 Cr | ₹94.86 Cr |
| attributable to NCI | -₹2.51 Cr | ₹9.11 Cr | ₹14.28 Cr | ₹7.11 Cr | ₹8.51 Cr | ₹3.3 Cr | ₹4.77 Cr | ₹6.24 Cr | ₹8.67 Cr | -₹1.28 Cr | -₹1.12 Cr | -₹1.21 Cr |
| Other Comprehensive Income | ₹44 Lakh | -₹74 Lakh | -₹57 Lakh | -₹57 Lakh | -₹1.95 Cr | -₹39 Lakh | -₹16 Lakh | -₹79 Lakh | -₹41.2 Lakh | -₹32.9 Lakh | -₹2.39 Cr | ₹7.8 Lakh |
| Total Comprehensive Income | ₹279.54 Cr | ₹108.09 Cr | ₹133.9 Cr | ₹124.53 Cr | ₹100.4 Cr | ₹86.54 Cr | ₹96.19 Cr | ₹88.63 Cr | ₹79.22 Cr | ₹101.13 Cr | ₹119.92 Cr | ₹93.73 Cr |
| EBITDA (computed) | ₹275.8 Cr | ₹281.63 Cr | ₹291.02 Cr | ₹279.4 Cr | ₹260.34 Cr | ₹254.53 Cr | ₹269.06 Cr | ₹251.63 Cr | ₹163.58 Cr | ₹179.71 Cr | ₹184.63 Cr | ₹170.73 Cr |
| Basic EPS | ₹20.60 | ₹7.32 | ₹8.82 | ₹8.66 | ₹6.90 | ₹6.15 | ₹6.73 | ₹6.11 | ₹5.22 | ₹7.55 | ₹9.08 | ₹6.97 |
| Diluted EPS | ₹20.57 | ₹7.31 | ₹8.81 | ₹8.64 | ₹6.89 | ₹6.14 | ₹6.72 | ₹6.10 | ₹5.21 | ₹7.54 | ₹9.06 | ₹6.97 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,821.74 Cr | ₹1,697.75 Cr | ₹1,486.71 Cr | ₹1,330.73 Cr | ₹1,215.73 Cr | ₹1,108.83 Cr | ₹1,020.23 Cr |
| Other Income | ₹98.31 Cr | ₹35.51 Cr | ₹34.83 Cr | ₹17.26 Cr | ₹28.99 Cr | ₹10 Cr | ₹14.73 Cr |
| Total Income | ₹1,920.05 Cr | ₹1,733.26 Cr | ₹1,521.53 Cr | ₹1,347.99 Cr | ₹1,244.72 Cr | ₹1,118.83 Cr | ₹1,034.96 Cr |
| Cost of Materials Consumed | ₹83.99 Cr | ₹68.35 Cr | ₹96.29 Cr | ₹114.13 Cr | ₹117.57 Cr | ₹99.43 Cr | ₹76.88 Cr |
| Purchases of Stock-in-Trade | ₹478.22 Cr | ₹474.44 Cr | ₹197.02 Cr | ₹113.76 Cr | ₹79.59 Cr | ₹111.65 Cr | ₹70 Cr |
| Changes in Inventories | ₹64.49 Cr | -₹43.54 Cr | -₹13.15 Cr | ₹8.5 Cr | ₹2.49 Cr | -₹12.57 Cr | ₹17.47 Cr |
| Employee Benefit Expense | ₹340.62 Cr | ₹361.92 Cr | ₹331.67 Cr | ₹252.52 Cr | ₹222.18 Cr | ₹207.02 Cr | ₹191.73 Cr |
| Finance Costs | ₹179.54 Cr | ₹220.24 Cr | ₹57.42 Cr | ₹20.81 Cr | ₹2.99 Cr | ₹77.8 Lakh | ₹1.85 Cr |
| Depreciation & Amortisation | ₹154.38 Cr | ₹181.77 Cr | ₹102.39 Cr | ₹64.66 Cr | ₹51.46 Cr | ₹37.64 Cr | ₹44.88 Cr |
| Other Expenses | ₹242.09 Cr | ₹350.03 Cr | ₹421.06 Cr | ₹336.71 Cr | ₹309.9 Cr | ₹285.99 Cr | ₹308.54 Cr |
| Total Expenses | ₹1,543.33 Cr | ₹1,613.21 Cr | ₹1,192.7 Cr | ₹911.08 Cr | ₹786.18 Cr | ₹729.94 Cr | ₹711.37 Cr |
| Profit Before Exceptional Items & Tax | ₹376.72 Cr | ₹120.05 Cr | ₹328.83 Cr | ₹436.91 Cr | ₹458.54 Cr | ₹388.89 Cr | ₹323.59 Cr |
| Exceptional Items | -₹14.67 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹362.05 Cr | ₹120.05 Cr | ₹328.83 Cr | ₹436.91 Cr | ₹458.54 Cr | ₹388.89 Cr | ₹323.59 Cr |
| Total Tax Expense | ₹118 Cr | ₹42.66 Cr | ₹29.12 Cr | ₹38.9 Cr | ₹41.35 Cr | ₹38.29 Cr | ₹32.32 Cr |
| Net Profit | ₹244.05 Cr | ₹77.39 Cr | ₹299.71 Cr | ₹398.01 Cr | ₹417.19 Cr | ₹350.61 Cr | ₹291.27 Cr |
| Other Comprehensive Income | ₹69 Lakh | -₹2.84 Cr | -₹2.76 Cr | -₹14.9 Lakh | -₹1.01 Cr | -₹1.28 Cr | -₹1.17 Cr |
| Total Comprehensive Income | ₹244.74 Cr | ₹74.55 Cr | ₹296.95 Cr | ₹397.86 Cr | ₹416.19 Cr | ₹349.33 Cr | ₹290.1 Cr |
| EBITDA (computed) | ₹710.64 Cr | ₹522.06 Cr | ₹488.64 Cr | ₹522.38 Cr | ₹512.98 Cr | ₹427.31 Cr | ₹370.33 Cr |
| Basic EPS | ₹17.86 | ₹5.69 | ₹22.04 | ₹29.27 | ₹30.70 | ₹25.82 | ₹21.23 |
| Diluted EPS | ₹17.83 | ₹5.68 | ₹22.01 | ₹29.23 | ₹30.70 | ₹25.80 | ₹21.21 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹5,777.94 Cr | ₹5,222.43 Cr | ₹5,349.57 Cr | ₹2,783.66 Cr |
| Non-current Assets | ₹4,755.13 Cr | ₹4,594.89 Cr | ₹3,473.02 Cr | ₹2,231.58 Cr |
| Current Assets | ₹1,022.81 Cr | ₹627.54 Cr | ₹1,876.55 Cr | ₹552.08 Cr |
| Property, Plant & Equipment | ₹124.19 Cr | ₹107.17 Cr | ₹148.25 Cr | ₹152.4 Cr |
| Inventories | ₹121.36 Cr | ₹191.25 Cr | ₹91.64 Cr | ₹63.7 Cr |
| Trade Receivables | ₹307.16 Cr | ₹236.19 Cr | ₹239.97 Cr | ₹229.22 Cr |
| Cash & Equivalents | ₹25.18 Cr | ₹84.34 Cr | ₹51.94 Cr | ₹47.48 Cr |
| Equity (Net Worth) | ₹3,195.46 Cr | ₹2,514.9 Cr | ₹2,524.02 Cr | ₹2,221.88 Cr |
| Equity Share Capital | ₹13.85 Cr | ₹13.62 Cr | ₹13.6 Cr | ₹13.6 Cr |
| Borrowings (Non-current) | ₹797.62 Cr | ₹1,632.64 Cr | ₹485.94 Cr | ₹209.47 Cr |
| Borrowings (Current) | ₹1,277.94 Cr | ₹580.31 Cr | ₹2,043.51 Cr | ₹107.4 Cr |
| Total Debt (computed) | ₹2,075.56 Cr | ₹2,212.95 Cr | ₹2,529.45 Cr | ₹316.87 Cr |
| Current Liabilities | ₹1,717.73 Cr | ₹993.94 Cr | ₹2,261.78 Cr | ₹283.77 Cr |
| Total Liabilities | ₹2,582.48 Cr | ₹2,707.53 Cr | ₹2,825.55 Cr | ₹561.77 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹563.94 Cr | ₹701.87 Cr | ₹336.29 Cr | ₹322.33 Cr | ₹369.41 Cr |
| Investing Cash Flow | -₹694.16 Cr | -₹358.99 Cr | -₹2,491.89 Cr | -₹513.3 Cr | -₹267.64 Cr |
| Financing Cash Flow | ₹71.06 Cr | -₹310.47 Cr | ₹2,160.06 Cr | ₹193.75 Cr | -₹88.42 Cr |
| Capital Expenditure | ₹49.39 Cr | ₹7.62 Cr | ₹349.05 Cr | ₹311.26 Cr | ₹53.28 Cr |
| Free Cash Flow (computed) | ₹514.55 Cr | ₹694.25 Cr | -₹12.76 Cr | ₹11.06 Cr | ₹316.13 Cr |
| Dividends Paid | ₹0 | ₹100.05 Cr | ₹10,000 | ₹99.91 Cr | ₹81.62 Cr |
| Net Change in Cash | -₹59.16 Cr | ₹32.41 Cr | ₹4.45 Cr | ₹2.78 Cr | ₹13.36 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹277.31 Cr | ₹315.29 Cr | ₹650.5 Cr | ₹578.64 Cr | ₹404.77 Cr | ₹399.73 Cr | ₹428.75 Cr | ₹456.69 Cr | ₹341.3 Cr | ₹324.41 Cr | ₹409.71 Cr | ₹411.29 Cr |
| Other Income | ₹26.97 Cr | ₹25.07 Cr | ₹23.59 Cr | ₹22.68 Cr | ₹16.75 Cr | ₹7.79 Cr | ₹13.62 Cr | ₹5.16 Cr | ₹20.39 Cr | ₹3.43 Cr | ₹6.98 Cr | ₹4.03 Cr |
| Total Income | ₹304.28 Cr | ₹340.36 Cr | ₹674.09 Cr | ₹601.32 Cr | ₹421.52 Cr | ₹407.52 Cr | ₹442.37 Cr | ₹461.85 Cr | ₹361.69 Cr | ₹327.85 Cr | ₹416.68 Cr | ₹415.31 Cr |
| Cost of Materials Consumed | ₹22.53 Cr | ₹17.05 Cr | ₹20.29 Cr | ₹24.12 Cr | ₹9.83 Cr | ₹10.93 Cr | ₹23.19 Cr | ₹24.4 Cr | ₹17.74 Cr | ₹23.75 Cr | ₹28.64 Cr | ₹26.17 Cr |
| Purchases of Stock-in-Trade | ₹122.95 Cr | ₹113.75 Cr | ₹134.83 Cr | ₹106.69 Cr | ₹119.02 Cr | ₹122.67 Cr | ₹112.34 Cr | ₹120.41 Cr | ₹37.17 Cr | ₹36.24 Cr | ₹51.43 Cr | ₹72.18 Cr |
| Changes in Inventories | -₹7.72 Cr | -₹20.77 Cr | ₹42.27 Cr | ₹50.71 Cr | -₹4.53 Cr | -₹14.52 Cr | -₹10.2 Cr | -₹14.29 Cr | ₹10.4 Cr | ₹4.65 Cr | -₹2.95 Cr | -₹25.25 Cr |
| Employee Benefit Expense | ₹78.67 Cr | ₹82.75 Cr | ₹85.42 Cr | ₹93.78 Cr | ₹81.41 Cr | ₹87.04 Cr | ₹89.72 Cr | ₹103.75 Cr | ₹79.52 Cr | ₹80.69 Cr | ₹81.1 Cr | ₹90.36 Cr |
| Finance Costs | ₹42.7 Cr | ₹45.2 Cr | ₹46.5 Cr | ₹45.14 Cr | ₹53.16 Cr | ₹54.65 Cr | ₹56.26 Cr | ₹56.17 Cr | ₹28.89 Cr | ₹15.14 Cr | ₹6.55 Cr | ₹6.84 Cr |
| Depreciation & Amortisation | ₹38.82 Cr | ₹38.66 Cr | ₹39.3 Cr | ₹37.6 Cr | ₹43.38 Cr | ₹46.68 Cr | ₹46.16 Cr | ₹45.55 Cr | ₹29.14 Cr | ₹28.08 Cr | ₹25 Cr | ₹20.16 Cr |
| Other Expenses | ₹39.1 Cr | ₹45.16 Cr | ₹70.81 Cr | ₹87.02 Cr | ₹78.07 Cr | ₹94.04 Cr | ₹78.88 Cr | ₹99.04 Cr | ₹117.08 Cr | ₹104.65 Cr | ₹107 Cr | ₹92.32 Cr |
| Total Expenses | ₹337.05 Cr | ₹321.8 Cr | ₹439.42 Cr | ₹445.06 Cr | ₹380.34 Cr | ₹401.49 Cr | ₹396.35 Cr | ₹435.03 Cr | ₹319.94 Cr | ₹293.2 Cr | ₹296.76 Cr | ₹282.79 Cr |
| Profit Before Exceptional Items & Tax | -₹32.77 Cr | ₹18.56 Cr | ₹234.67 Cr | ₹156.26 Cr | ₹41.18 Cr | ₹6.03 Cr | ₹46.02 Cr | ₹26.82 Cr | ₹41.75 Cr | ₹34.64 Cr | ₹119.92 Cr | ₹132.52 Cr |
| Exceptional Items | ₹0 | -₹14.67 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹32.77 Cr | ₹3.89 Cr | ₹234.67 Cr | ₹156.26 Cr | ₹41.18 Cr | ₹6.03 Cr | ₹46.02 Cr | ₹26.82 Cr | ₹41.75 Cr | ₹34.64 Cr | ₹119.92 Cr | ₹132.52 Cr |
| Total Tax Expense | -₹24.17 Cr | ₹80 Lakh | ₹85.1 Cr | ₹56.27 Cr | ₹10.71 Cr | ₹4.25 Cr | ₹17.92 Cr | ₹9.78 Cr | ₹2.24 Cr | ₹2.99 Cr | ₹2.11 Cr | ₹21.78 Cr |
| Net Profit | -₹8.6 Cr | ₹3.09 Cr | ₹149.57 Cr | ₹99.99 Cr | ₹30.47 Cr | ₹1.78 Cr | ₹28.1 Cr | ₹17.04 Cr | ₹39.51 Cr | ₹31.66 Cr | ₹117.81 Cr | ₹110.74 Cr |
| Other Comprehensive Income | ₹2.19 Cr | -₹50 Lakh | -₹50 Lakh | -₹50 Lakh | -₹1.59 Cr | -₹42 Lakh | -₹11 Lakh | -₹72 Lakh | -₹65.6 Lakh | -₹15.1 Lakh | -₹2.02 Cr | ₹6.5 Lakh |
| Total Comprehensive Income | -₹6.41 Cr | ₹2.59 Cr | ₹149.07 Cr | ₹99.49 Cr | ₹28.88 Cr | ₹1.36 Cr | ₹27.99 Cr | ₹16.32 Cr | ₹38.85 Cr | ₹31.5 Cr | ₹115.79 Cr | ₹110.81 Cr |
| EBITDA (computed) | ₹48.75 Cr | ₹102.42 Cr | ₹320.47 Cr | ₹239 Cr | ₹137.72 Cr | ₹107.36 Cr | ₹148.44 Cr | ₹128.54 Cr | ₹99.78 Cr | ₹77.87 Cr | ₹151.47 Cr | ₹159.53 Cr |
| Basic EPS | ₹-0.63 | ₹0.23 | ₹10.98 | ₹7.34 | ₹2.24 | ₹0.13 | ₹2.06 | ₹1.25 | ₹2.90 | ₹2.33 | ₹8.66 | ₹8.14 |
| Diluted EPS | ₹-0.63 | ₹0.23 | ₹10.96 | ₹7.33 | ₹2.23 | ₹0.13 | ₹2.06 | ₹1.25 | ₹2.90 | ₹2.33 | ₹8.65 | ₹8.13 |
Shareholding Pattern of Eris Lifesciences Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 53.92%, foreign institutional investors hold 6.39%, domestic institutional investors hold 20.35%, retail and other public shareholders hold 19.33% of Eris Lifesciences Limited. The company had 51,656 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 53.92% | 54.85% | 54.85% | 54.83% | 54.85% | 54.86% |
| Public | 46.08% | 45.15% | 45.15% | 45.17% | 45.15% | 45.14% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Promoters | 53.92% | 54.85% | 54.90% | 52.86% | 52.66% | 54.13% | 55.55% | 56.10% | 55.93% |
| Public | 46.08% | 45.15% | 45.10% | 47.14% | 47.34% | 45.87% | 44.45% | 43.90% | 44.07% |
| Promoter change (YoY, %pts) | -0.93 | -0.05 | +2.04 | +0.20 | -1.47 | -1.42 | -0.55 | +0.17 | - |
Board & Governance of Eris Lifesciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Eris Lifesciences Limited has 8 directors - 4 independent and 4 executive. The board is chaired by AMIT INDUBHUSHAN BAKSHI.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| AMIT INDUBHUSHAN BAKSHI | Executive Director · CEO-MD · Chairperson | 2007-01-27 | 1 |
| KAUSHAL KAMLESH SHAH | Executive Director | 2020-08-04 | 1 |
| KRISHNAKUMAR VAIDYANATHAN | Executive Director | 2020-12-20 | 1 |
| INDERJEET SINGH NEGI | Executive Director | 2007-01-27 | 1 |
| KALPANA VASANTRAI UNADKAT | Non-Executive - Independent Director | 2021-01-05 | 3 |
| SUJESH VASUDEVAN | Non-Executive - Independent Director | 2022-07-25 | 2 |
| PRASHANT GUPTA | Non-Executive - Independent Director | 2018-04-30 | 1 |
| VINEET VARMA | Non-Executive - Independent Director | 2026-03-14 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | KALPANA VASANTRAI UNADKAT (Chairperson), SUJESH VASUDEVAN, PRASHANT GUPTA, VINEET VARMA |
| Nomination and remuneration committee | SUJESH VASUDEVAN (Chairperson), PRASHANT GUPTA, KALPANA VASANTRAI UNADKAT, VINEET VARMA |
| Stakeholders Relationship Committee | KALPANA VASANTRAI UNADKAT, SUJESH VASUDEVAN (Chairperson), INDERJEET SINGH NEGI |
| Risk Management Committee | KRISHNAKUMAR VAIDYANATHAN (Chairperson), KALPANA VASANTRAI UNADKAT, SACHIN SHAH |
| Corporate Social Responsibility Committee | INDERJEET SINGH NEGI (Chairperson), KAUSHAL KAMLESH SHAH, SUJESH VASUDEVAN, VINEET VARMA |
Group Structure of Eris Lifesciences Limited
Eris Lifesciences Limited has 6 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Eris Lifesciences Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Eris Healthcare Private Limited | U24211GJ2013PTC113419 | - |
| Eris Therapeutics Limited | U24230GJ2021PLC123519 | - |
| Aprica Healthcare Limited | U24232GJ2011PLC112374 | - |
| Eris Pharmaceuticals Private Limited | U33100UP2020PTC128964 | - |
| Eris M. J. Biopharm Private Limited | U51397GJ2002PTC112851 | - |
| Eris Oaknet Healthcare Private Limited | U74999MH2011PTC296817 | - |
Showing major subsidiaries. Total: 6.
Charges & Borrowings of Eris Lifesciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Apr 2025 | Hdfc Bank Limited | ₹150 Cr | Open |
| 27 Dec 2023 | Hdfc Bank Limited | ₹212 Cr | Open |
| 21 Dec 2023 | Citi Bank N.A. | ₹280 Cr | Open |
| 21 Aug 2023 | Citi Bank N.A. | ₹120.82 Cr | Open |
| 26 Jul 2023 | Axis Bank Limited | ₹337 Cr | Open |
Total charge records: 12 View all charges
Employees and EPFO Compliance at Eris Lifesciences Limited
Eris Lifesciences Limited has a workforce of 3,131 employees as of Mar 06, 2025.
Employee Count & EPFO Data of Eris Lifesciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Eris Lifesciences Limited
GSTIN & GST Filing Data of Eris Lifesciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Eris Lifesciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Eris Lifesciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Eris Lifesciences Limited
MSME Payment Delays by Eris Lifesciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Eris Lifesciences Limited
Subsidiaries & Group Companies of Eris Lifesciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Eris Lifesciences Limited with ownership details.
MCA Filings & Documents of Eris Lifesciences Limited
MCA Filings & Documents of Eris Lifesciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Eris Lifesciences Limited
Recent News on Eris Lifesciences Limited
Frequently Asked Questions about Eris Lifesciences Limited
Eris Lifesciences Limited is an active public limited company in the pharma sector based in Ahmedabad, Gujarat, India. It was incorporated on 25 January 2007 (19+ years old) and is registered under CIN L24232GJ2007PLC049867. Listed on BSE: 540596 and NSE: ERIS. The company has 3,131 employees.
Eris Lifesciences Limited reported revenue of ₹2,912 Cr for FY 2025 (up 43.00% YoY).
The current directors of Eris Lifesciences Limited are:
The primary industry of Eris Lifesciences Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Eris Lifesciences Limited is listed on both BSE (code: 540596) and NSE (symbol: ERIS).
Eris Lifesciences Limited can be reached at the registered office: Shivarth Ambit Plot No 1422 Ramdas Road Off Sbr Near Swati Bungalows Bodakdev, Ahmedabad, Gujarat, India – 380054, or through the website eris.co.in.